Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Onyx Weight Loss

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Onyx Weight Loss
Site position #408

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 58.8/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +49
92
43
Dose & formulationCoreAge Rx +24
88
64
Clinical oversightCoreAge Rx +18
93
75
Labs & monitoringCoreAge Rx +27
90
63
FulfillmentCoreAge Rx +42
95
53
Contract termsCoreAge Rx +12
67
55
CoreAge Rx · top barOnyx Weight Loss · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxOnyx Weight Loss
WeighScore89.5/10058.8/100
GradeB+C
Site position#1#408
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$228/mo (starting dose, compounded)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$280/mo (starting dose, compounded)
CoverageUS only; therapy-specific state restrictions apply8 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Onyx Weight Loss

Site position #408 · C

Strengths

  • Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
  • Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
  • Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
  • Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
  • Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team

What to consider

  • Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
  • No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
  • Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
  • Labs not included or mentioned; no baseline bloodwork protocol published
  • Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard